OUR PURPOSE

Empowering Unprecedented Insights into Patient Health and Disease

REALM IDx, Inc. is a healthcare company pioneering the field of integrated diagnostics, a new frontier of advanced clinical science that brings together genomics, radiology, pathology, and sophisticated artificial intelligence to derive actionable insights that can predict, diagnose, and treat disease.

We believe today’s innovations in integrated diagnostics will become tomorrow’s standard of care throughout the healthcare continuum. At REALM, it is our mission to continuously seek the answers within to improve quality of life for all.

LEADERSHIP

Trailblazing the Field of Integrated Diagnostics

Board of Directors

Kiyotaka Fujii
Kiyotaka Fujii has served as a Director of our board since October 2018. He served as our President from November 2018 to November 2019, as our Chief Executive Officer from November 2018 to May 2021, and as a Chairman of the Board for both Ambry Genetics and Invicro. In addition, Fujii has been President, Global Healthcare, and Senior Executive Vice-President and Executive Officer of KMI since 2016. Fujii’s extensive business career ranges from medical services, information technology, and consumer products to investment banking. Read more +

He has held several Japan CEO positions with top global companies since 1997, including SAP, Louis Vuitton, Cadence Design Systems, and Quintiles Transnational. From 2012 to 2015, he served at Olympus as the first independent board member to rebuild its governance and businesses. From 1986 to 1993, Fujii held the role as the first Japanese M&A investment banker in New York with Credit Suisse First Boston and Goldman Sachs. He began his career with McKinsey as the first hire from a Japanese university. As the author of “Global Mind,” a top-selling Japanese business book, Fujii is often consulted for his perspective as a global business leader in Japan by the government and news media. He received an M.B.A. from the Harvard Business School in 1986 and a B.A. in Law from the University of Tokyo in 1981. Show less –

Aaron Elliott, Ph.D.
Dr. Elliott has served as our Chief Executive Officer and President since May 2021, has been a member of the Board of Directors of Ambry since October 2017, and previously served as Chief Executive Officer of Ambry from 2016 until May 2021. Aaron joined Ambry in 2008 as a scientist in the research and development department working closely on the development of comprehensive molecular diagnostic tests. An innovator in complex genetic testing, Aaron has been involved in the conception and implementation of many of the diagnostics industry’s first-to-market tests and technologies, including the first commercial NGS assay, CLIA/CAP Exome test and hereditary cancer panels among others. Read more +

Aaron helped guide Ambry through extreme periods of growth, including its acquisition by Konica Minolta PM, Inc. Over the years, he has held many leadership positions at Ambry, including Director of Genomic Services, Chief Operating Officer and Chief Scientific Officer. Aaron began his career as a Postdoctoral Fellow at the Novartis Institute of Functional Genomics in San Diego where he conducted research on potential drug targets for chemotherapeutic resistance and tumor formation. As part of this research, Aaron helped identify the first mitochondrial ABC transporter in cancer cells, which are responsible for multi-drug resistance in many solid tumors. A graduate of Franklin and Marshall College with a B.S. in Biology, Aaron conducted his Ph.D. Genetics training at Thomas Jefferson University and The Johns Hopkins University School of Medicine.Show less –

A. Gregory Sorensen, M.D.

Dr. Gregory Sorensen has been a member of the board of directors of Invicro since January 2018 and has been a consultant advising KMI on the strategic and scientific aspects of KMI’s global health care business since June 2016. He has been the Chief Executive Officer and co-founder of DeepHealth (now the AI division of RadNet) since October 2015 and previously served as the President and Chief Executive Officer of Siemens Healthcare North America from June 2011 to September 2015. Read more +

Prior to Siemens, he served as a neuroradiologist, physician scientist, and professor at Massachusetts General Hospital and Harvard Medical School. Dr. Sorensen has served as a supervisory board member for Fresenius Medical Care since May 2021, a supervisory board member of Siemens Healthineers since March 2018, and the executive chairman of IMRIS Deerfield Imaging since October 2015. He also works with other emerging healthcare businesses. Dr. Sorensen served as a board member of the nonprofit Research!America until March 2020, and as an Advisory Council member to the nonprofit National Institute of Biomedical Imaging and Bioengineering until February 2019. He earned a B.S. in Biology in 1984 from California Institute of Technology, an M.S. in Computer Science in 1987 from Brigham Young University, and an M.D. in 1989 from Harvard Medical School. Show less –

Executive Team

Aaron Elliott, Ph.D., Chief Executive Officer
Dr. Aaron Elliott has served as our Chief Executive Officer and President since May 2021, has been a member of the Board of Directors of Ambry since October 2017 and previously served as Chief Executive Officer of Ambry from 2016 until May 2021. Aaron joined Ambry in 2008 as a scientist in the research and development department working closely on the development of comprehensive molecular diagnostic tests. An innovator in complex genetic testing, Aaron has been involved in the conception and implementation of many of the diagnostic industry first-to-market tests and technologies including the first commercial NGS assay, CLIA/CAP Exome test, and hereditary cancer panels among others. Read more +

Aaron helped guide Ambry through extreme periods of growth, including its acquisition by Konica Minolta PM, Inc. Over the years, he has held many leadership positions at Ambry, including Director of Genomic Services, Chief Operating Officer, and Chief Scientific Officer. Aaron began his career as a Postdoctoral Fellow at the Novartis Institute of Functional Genomics in San Diego, where he conducted research on potential drug targets for chemotherapeutic resistance and tumor formation. As part of this research, he helped in identifying the first mitochondrial ABC transporter in cancer cells, which are responsible for multi-drug resistance in many solid tumors. A graduate of Franklin and Marshall College with a B.S. in Biology, Aaron conducted his Ph.D. Genetics training at Thomas Jefferson University and The Johns Hopkins University School of Medicine. Show less –

George Abe, Chief Operating Officer
George Abe has served as our Chief Operating Officer since August 2021. Prior to that, he served as Chief Business and Strategy Officer for Invicro, responsible for establishing and growing Invicro’s emerging Advanced Pathology Services business and leading the company’s global corporate development efforts. George has over 30 years of experience in creating value in the life science and high technology industries. Read more +

He has been involved in numerous transactions including mergers, acquisitions, divestitures, and strategic licensing. He has also been the CEO of three life science companies, two of which focused on developing novel imaging solutions for oncology and neuroscience research and diagnostics. George has also served on a variety of private, public, and not-for-profit boards. He holds a bachelor’s degree in engineering from Trinity College, a master’s degree in engineering from the University of Connecticut and is a graduate of the Greater Boston Executive Program at MIT, Sloan School of Business. Show less –

Michelle Smith, General Counsel & Secretary
Michelle Smith is the General Counsel and Secretary of REALM where she oversees all legal and governance matters. Michelle also serves as the General Counsel and Secretary of Ambry Genetics. Prior to joining REALM, Michelle practiced intellectual property law at the international law firm of Jones Day in Irvine, California, and general corporate law at The Patrón Spirits Company in Las Vegas, Nevada. Read more +

In law school, she served as an extern for the U.S. Attorney’s Office, Central District in Santa Ana, California. Michelle graduated summa cum laude from the University of California Los Angeles. She then earned her J.D. from the University of Southern California where she served on the Southern California Law Review. She is admitted to practice law in the State of California. Show less –

Mickie Henshall, Chief Marketing Officer
Mickie Henshall has served as our Chief Marketing Officer since September 2021. Prior to that, she served as the Senior Vice President of Marketing at Ambry Genetics, where she was responsible for the corporate brand and marketing strategies. For more than 20 years, Mickie has focused on the health sciences, spanning medical devices, molecular diagnostics, and point-of-care hospital testing. As a change-agent, Mickie has specialized in transforming public and private equity-backed organizations into high-growth commercial companies through her talent in brand creation, portfolio development, and marketing strategy. Read more +

As one of the first diagnostics commercial employees at Illumina, her deep understanding of science, regulatory compliance, and commercial execution enabled her to lead Illumina to its first FDA 510(k) and the company’s clinical market strategy. Mickie’s leadership includes global experience, having led regional marketing teams in Europe, China, and Australia. Her market knowledge has made her an integral member of merger and acquisition teams, most recently through the successful sale of Accriva Diagnostics to Werfen Life, a multi-billion-dollar Spanish IVD company. Henshall earned a B.A. in Integrative Biology from University of California, Berkeley. Show less –

Catherine Suh, SVP, Human Resources
Catherine Suh has served as our SVP, Human Resources since December 2021. Prior to that, she served as the Vice President of People at Ambry Genetics. She joined in 2016 during a time of hypergrowth for the company to implement a scalable infrastructure that could support a dynamically growing organization. Prior to Ambry, she was a HR Business Partner at Experian Consumer Services and was involved in several acquisitions and a divestiture. For nearly 15 years, Catherine has worked in highly regulated environments in healthcare, financial technology and biotech. She has worked closely alongside leaders during times of growth and transformation to align the HR strategy with the business strategy. Catherine earned an MBA and a bachelor’s degree in Psychology from the University of California, Irvine.

Our Companies

The strength of REALM’s integrated diagnostics approach can be attributed to the world-class businesses that are a part of the corporation. These organizations are centers of excellence in their respective fields and share a commitment to transform healthcare with next-generation solutions.

Ambry Genetics

Ambry Genetics excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. Its unparalleled track record of discoveries over 20 years and a growing database that continues to expand in collaboration with academic, corporate, and pharmaceutical partners enables them to be first to market with innovative products and comprehensive analyses that empower clinicians to confidently inform patient health decisions.

ambrygen.com